the present invention relates to organic compound chemistry, pharmacology and medicine and relates to therapy for obesity, psoriasis, crohn's disease, colitis, irritable bowel syndrome, diarrhea, nausea and vomiting, as well as a number of other diseases associated with cathepsin s activity, type 1 cannabinoid receptors, type 1 and 2 tachykinin receptors, type 1 and 2 prokineticin receptors, type 1 bradykinin receptors, mc4r melanocortin receptors, 5-ht2b serotonin receptors and nb-kb signaling pathway using a compound (i) of benzyl (2s) -2- [2- (4-hydroxyphenyl) acetamido] -3-phenylpropanoate. this compound and pharmaceutically acceptable adducts, solvates and hydrates thereof are a cathepsin inhibitor, type 1 cannabinoid receptor antagonist, type 1 and 2 tachykinin receptor antagonist, type 1 and 2 prokineticin receptor antagonist, antagonist type 1 bradykinin receptor, melanocortin mc4r receptor antagonist, serotonin 5-ht2b receptor antagonist and inhibitor of the nb-kb signaling pathway. the invention also relates to pharmaceutical compositions that comprise a therapeutically effective amount of the compound according to the invention.a presente invenção refere-se à química de compostos orgânicos, farmacologia e medicina e refere-se à terapia para obesidade, psoríase, doença de crohn, colite, síndrome do intestino irritável, diarreia, náuseas e vômitos, bem como uma série de outras doenças associadas à atividade de catepsina s, receptores canabinoides de tipo 1, receptores de taquiquinina de tipos 1 e 2, receptores de proquineticina de tipos 1 e 2, receptores de bradiquinina de tipo 1, receptores de melanocortina mc4r, receptores de serotonina 5-ht2b e via de sinalização nb-kb usando um composto (i) de (2s)-2-[2-(4-hidroxife-nil) acetamido]-3-fenilpropanoato de benzila. este composto e adutos, solvatos e hidratos farmaceuticamente aceitáveis dos mesmos são um inibidor de catepsina s, antagonista do receptor canabinoide de tipo 1, antagonista dos receptores de ta
